All News

Komen vows to drive breakthroughs for the most-deadly breast cancers and educate those who believe breast cancers are easily treated or always curable.

How do we describe the type of fatigue cancer survivors feel? Here is one explanation.

For Metastatic Breast Cancer Awareness Day on October 13th, 2019, here’s a round-up of fast facts and the latest news and updates in this disease space.

A prolonged and doctor-sanctioned respite from scans gave one woman time to re-evaluate her life with metastatic breast cancer.

It is hard for me to have regrets, especially when it comes to cancer treatment. I am thankful for every step of my journey. At the same time, voicing a few of my regrets after all this time might help others. A cancer patient needs as much information as possible to make the journey work.

From a health update from Alex Trebek to the sudden death of Bernie Sander’s daughter-in-law, here’s what is making headlines in the cancer space this week.

A four-time breast cancer survivor and winner of CURE®’s art cover contest shares what drives her passion.

A phase 3 trial compared Keytruda versus chemotherapy for patients with advanced pretreated malignant pleural mesothelioma.

The pink and blue conundrum makes its October reappearance once again.

After receiving a stage 4 brain cancer diagnosis, a young mother traveled from Mexico to Chicago for treatment.

The IMvigor130 trial showed chemotherapy plus immunotherapy in patients with metastatic urothelial cancer could prolong the time to disease progression.

A friend of mine told me the other day how a new song on the radio makes her think of my late husband Matthew. I remember them, too, I said. But I didn't, however, tell her about all the memories of him that are starting to fade.

A physical therapist and testicular cancer survivor shares the health benefits of rehabilitation after cancer.

Two patients with metastatic breast cancer shared their journeys, inspiring fellow patients at Susan G. Komen Greater New York City’s New York Metastatic Breast Cancer Conference.

An ovarian cancer survivor shares what she wishes she had known then with those who are newly diagnosed.

A blood test may help to identify the best treatment option for patients with ALK-positive, advanced non-small cell lung cancer, sparing patients from having to undergo an invasive biopsy.

Dr. Patrick I. Borgen discussed estrogen receptor-positive breast cancer and why it is important for patient to understand what this means for their treatment.

Obese patients being treated for breast or prostate cancer showed higher levels of mental and physical distress than nonobese patients with these diseases, but the pattern did not hold true in those with colorectal cancer, according to a study.

Cancer can bring others to love into our lives. This can be costly, but I choose to believe it is worth it.

A recent study found no different in disease recurrence among men with prostate cancer when they were given radiation after surgery or not.

How the high cost of cancer leaves many choosing between physical, financial and emotional health.

A cancer survivor and clutter-clearing author shares autumnal time management tips.

The tumors of patients with non-small cell lung and renal cell cancer shrunk following treatment with pegilodecakin plus immunotherapy.

Reading, writing, art, music... CURE recently asked its social media audience to share the creative outlets and activities that have helped them on their cancer journey. Here are some of their responses – in the hopes of helping others find a new hobby of their own.

Like many people who receive a cancer diagnosis, one survivor questions the reason.

From Matthew Knowles revealing a male breast cancer and BRCA2 diagnosis to a sarcoma survivor donating thousands of toys in lieu of birthday presents, here’s what is making headlines in the cancer space this week.

Knowing your family history is the first preventative step any woman can take to avoid a diagnosis of ovarian cancer.

Phase 3 trial findings showed that treatment with Lynparza delayed disease progression by about four months compared with newer hormonal agents in pre-treated patients with metastatic castration-resistant prostate cancer and faulty DNA repair genes.